3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
8
Phase 3
4
Phase 2/3
2
Phase 1
2
Phase NA
1
Phase 1/2
1
Status
Unknown
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
265
Carcinoma, Non-Small-Cell Lung
219
Neoplasms
218
Leukemia, Myeloid, Acute
193
Multiple Myeloma
178
Colorectal Neoplasms
174
Melanoma
165
Prostatic Neoplasms
163
Lymphoma
145
Leukemia
142
Lymphoma, Non-Hodgkin
133
Glioblastoma
130
Pancreatic Neoplasms
127
Neoplasm Metastasis
118
Lung Neoplasms
118
Leukemia, Lymphocytic, Chronic, B-Cell
118
Ovarian Neoplasms
112
Precursor Cell Lymphoblastic Leukemia-Lymphoma
106
Recurrence
97
Myelodysplastic Syndromes
93
Hodgkin Disease
92
Lymphoma, Large B-Cell, Diffuse
89
Lymphoma, Follicular
89
Lymphoma, Mantle-Cell
83
Head and Neck Neoplasms
79
Carcinoma, Renal Cell
79
Brain Neoplasms
77
Sarcoma
73
Carcinoma, Hepatocellular
73
Squamous Cell Carcinoma of Head and Neck
71
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Completed
×
Pathologic Complete Response
×
Clear all
NCT02789254
2023-12-28
FLYSYN-101
Synimmune GmbH
Phase 1/2
Completed
31 enrolled